Diffuse Large B-Cell Lymphoma — Trials

Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 355
Recruiting: 190
Ph III recruiting: 16
Growth YoY: −11.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (177)

clinicaltrialsPublishedShowing 251–300 of 421 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04156828	Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma	terminated	Phase 1	12	University of WashingtonOTHER	1	Jun 29, 2023	clinicaltrials
NCT03028103	Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients	completed	Phase 1	32	Epizyme, Inc.